Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02602067
Other study ID # TENATUMOMAB/ST2146-CR-14-001
Secondary ID 2014-003832-38
Status Terminated
Phase Phase 1
First received
Last updated
Start date November 2015
Est. completion date April 30, 2017

Study information

Verified date January 2018
Source sigma-tau i.f.r. S.p.A.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Tenatumomab is a Sigma-Tau developed new anti-Tenascin antibody. It is a murine monoclonal antibody directed towards Tenascin-C. By means of this antibody, Tenascin-C expression was studied on a commercial tissue array slides each carrying malignant breast, colorectal, lung, ovarian or B and T cell Non-Hodgkin Limphoma tissue sections. All these cancers type showed positivity to Tenascin-C between the 64% and 13.3%. Consequently, Sigma-tau is exploring the use of the 131I-labeled Tenatumomab for anti-cancer radioimmunotherapy.


Description:

This will be an open-label dose escalation study. The study will be conducted in two steps:

1. STEP A aims to identify the optimal amount of antibody to convey the specific radio-label activity of radionuclide.

2. STEP B will be conducted with the amount of antibody chosen in STEP A, and an escalating radio-labeled therapeutic dose response curve will be performed (3.5 to 5.5 GBq) A maximum of 36 evaluable patients suffering from treatment-refractory Tenascin-C positive tumors.

This dose escalation study will be evaluated using descriptive statistics: no sample size calculation was performed

Primary objectives

1. To identify the Maximum Tolerated Dose (MTD) and assess Safety and Tolerability of i.v. infused 131I-Tenatumomab.

2. To identify the optimal amount of unlabeled Tenatumomab able to convey 131I- Tenatumomab with the highest Tumor/nonTumor ratio.

3. To evaluate the whole body Dosimetry (safety dosimetry) and Tumor to normal tissue ratio (T/nT ratio, referred to AUC) of i.v.infused 131I-Tenatumomab.

4. To evaluate intra-lesional distribution and retention of 131I-Tenatumomab and to record individual lesion dosimetry.

5. To evaluate systemic biodistribution, pharmacokinetics, urinary excretion and dose linearity of 131I-Tenatumomab.

Secondary objectives

1. To evaluate proportional 131I-Tenatumomab tumor binding, as a function of the total load.

2. To evaluate Pharmacokinetics of Tenatumomab (protein and protein related materials) in serum.

3. To evaluate preliminary Efficacy of 131I-Tenatumomab based on disease response rate (Complete Response, Partial Response, Stable Disease) and patient's general clinical condition by ECOG performance status assessment.


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date April 30, 2017
Est. primary completion date April 30, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- 1. Written informed consent.

- 2. A patient who has (a) a histologically documented advanced tumor that has relapsed from, or is refractory to, standard treatment and for which no other standard treatment is available and (b) confirmed Tenascin-C expression obtained through a biopsy on at least one reachable tumor lesion.

These patients will have failed one or more prior therapeutic line and had assessable and measurable disease expression, but were not considered eligible for other standard approaches with curative intent, as assessed by the Investigator.

- 3. Agreement to hemopoietic stem cell collection procedures (the procedure will be performed upon clinical evaluation of the Investigator and if deemed necessary in the interest of the patient).

- 4. Male or female =18 years of age

- 5. Eastern Cooperative Oncology Group (ECOG), or WHO performance status of = 2 or Karnofsky > 60

- 6. Life expectancy of at least 3 months.

- 7. Negative pregnancy test for all women of child-bearing potential. Appropriate contraception (one highly effective method or a combination of acceptable methods) is to be used during the study period and until 90 days after the last follow-up visit (End of Study Visit)

- 8. Hematological, thyroid, liver, cardiac and renal function test results = grade 2 toxicity (according to US National Cancer Institute's "Common Terminology Criteria for Adverse Events v4.03 [CTCAE]"), e.g.:

Haematology:

- Hematocrit = 30%

- Hemoglobin = 9.0 g/dl

- White blood cell count = 3 x 109/L

- Neutrophils > 1.5 x109/L

- Platelets = 100x 109/L

Thyroid:

- Free-Triiodothyronine and Free-Thyroxine = 3 times upper limit of normal or >3 times lower limit of normal.

Liver:

- Alanine transaminase, Aspartate transaminase, Alkaline Phosphatase = 2.5 times institutional upper limit of normal (ULN) or =5 x ULN in presence of liver metastases.

- Bilirubin = 1.5 x ULN or =3 x ULN in presence of liver metastases.

Renal:

- Urine protein: =30 mg/dl or dipstick: =3

- eGFR=60 ml/min/1.73 m2 (with Chronic kideny disease-Epidemiology collaboration formula)

Cardiac

• Resting Ejection Fraction (EF) = 50%

Exclusion Criteria:

- 1. Known hypersensitivity to Tenatumomab, Iodine or any excipient.

- 2. Active infection at screening or history of severe infection within the previous 2 months, if considered clinically relevant by the Investigator.

- 3. Positive test to Human Immunodeficiency Virus (HIV) and/or chronically active Hepatitis B or C.

- 4. Patients with primary Central nervous system tumor or cerebral metastases.

- 5. Administration of another investigational medicinal product within 45days before the screening period.

- 6. Previous treatment with any radiopharmaceutical within a period corresponding to 8 half-lives of the radionuclide used prior to the administration of study drug.

- 7. History of somatic or psychiatric disease/condition that may interfere with the objectives of the study.

- 8. Major illness, trauma, or surgery within 2 weeks before the screening period, if considered clinically significant by the Investigator.

- 9. Patient who underwent chemotherapy and/or radiation therapy and/or treatments with biologics (which are not to be of murine origin) within 4 weeks before the screening period.

- 10. Women who are breast feeding, due to the potential risk of damage to the infant.

- 11. Men unwilling to use appropriate contraceptive methods during the study and up to 90 days after the last follow-up visit (End of Study Visit).

- 12. Bladder catheterization cannot be performed, or the patient is unwilling to be catheterized if necessary.

- 13. Murine antibodies treated patients. It is at the discretion of the Investigator to exclude patients who have worsened considerably from screening to Day -1.

Study Design


Intervention

Combination Product:
131I-Tenatumomab
I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C

Locations

Country Name City State
France Institut Bergonnie Bordeaux
France Centre Leon Berard Lyon
France Icm Val D'Aurelle Montpellier
Italy Istituto Nazionale Dei Tumori Irccs - Fondazione "G. Pascale" Naples
Italy University of Study of Pisa Pisa
Italy S. Maria Nuova Hospital - Irccs Reggio Emilia
Italy Humanitas Clinical Institute Rozzano Mi

Sponsors (2)

Lead Sponsor Collaborator
sigma-tau i.f.r. S.p.A. Medpace, Inc.

Countries where clinical trial is conducted

France,  Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other Tumor response Tumor response according to Response Evaluation Criteria in Solid Tumors RECIST V 1.1 or PERCIST 1 year
Primary Dose Limiting Toxicity evaluated using NCI Common Toxicity Criteria (CTCAE 4.03) no more details necessary up to six weeks
Secondary Adverse Events no more details necessary up to 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT05540340 - A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03484702 - Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma Phase 2
Completed NCT01410630 - FLT-PET/CT vs FDG-PET/CT for Therapy Monitoring of Diffuse Large B-cell Lymphoma
Active, not recruiting NCT05024045 - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers Phase 1
Completed NCT06190457 - Safety and Efficacy of Intrathecal Rituximab in 16 Children of Stage Ⅲ、ⅣNon-Hodgkin Lymphoma
Completed NCT02369016 - Phase III Copanlisib in Rituximab-refractory iNHL Phase 3
Recruiting NCT01676805 - Tissue Collection for Studies of Lymph Cancer
Terminated NCT00916045 - Pilot Study of Unrelated Cord Blood Transplantation Phase 2
Terminated NCT00529503 - A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL Phase 2
Completed NCT00534989 - Use of FDG PET as Predictor of Residual Disease and Subsequent Relapse in Patients With NHL and HD Undergoing HDC and ASCT N/A
Withdrawn NCT00538096 - A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma Phase 1
Completed NCT00156013 - Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL) Phase 1/Phase 2
Withdrawn NCT00319332 - A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen Phase 3
Completed NCT00322842 - Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients Phase 2
Completed NCT00141297 - A Study Of Oral Palbociclib (PD-0332991), A Cyclin-Dependent Kinase Inhibitor, In Patients With Advanced Cancer Phase 1
Completed NCT02509039 - A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL) Phase 1
Completed NCT00268203 - Expanded Access Study Of BEXXAR® For Low Grade And Transformed Low-Grade Non-Hodgkin's Lymphoma Phase 2
Completed NCT01573000 - A Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma (NHL) Phase 2
Completed NCT03289182 - An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)